Abbvie pays handsomely to join the CD20 bispecific brawl, handing over $750m to Genmab for access to a project that trails the competition.
Arcus insists that its new partnership is a good deal, but shareholders make their feelings known.
Five months after Novartis paid $9.7bn for the RNAi project’s maker, Blackstone has put down a $1bn bet on a partial royalty interest.
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.
Drug developers have directed almost half of their dealmaking firepower at oncology projects over the past five years, with cardiovascular a distant second.
Pfizer’s chief executive has pledged to throw money at the pharma giant’s thin pipeline and shirk financial engineering, but only canny deal-making will keep investors on…
Last year saw a dip in licensing deals across biopharma, though up-front payments held up and in some areas jumped considerably.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.